IRAK4

Class

Oral IRAK4 chimeric degradation-activating compound (CDAC)

IRAK4 (interleukin-1 receptor-associated kinase 4) is an enzyme positioned near the start of a major inflammatory signaling pathway. It becomes active when innate immune receptors—Toll-like receptors and interleukin-1 family receptors—sense microbial components or tissue-damage signals. Once engaged, IRAK4 helps assemble a multiprotein signaling complex that triggers downstream cascades, notably NF-κB and MAPK signaling, prompting cells to release inflammatory mediators such as TNF, IL-6, and IL-1β. Because this pathway underlies both chronic inflammatory disease and certain blood cancers driven by mutations in the adaptor protein MyD88, IRAK4 has become an attractive drug target. Conventional small-molecule inhibitors block the enzyme's catalytic activity, but IRAK4 also performs a structural, non-enzymatic role in holding the signaling complex together, a scaffolding function that can persist even when the catalytic site is chemically blocked. Degrader compounds, such as the chimeric degradation-activating compound referenced here, address this limitation by eliminating the entire IRAK4 protein rather than only silencing its enzymatic function, aiming for more complete disruption of the pathway. This mechanism is broadly relevant to autoimmune and inflammatory conditions, where excessive innate immune signaling contributes to tissue damage, and to lymphomas that depend on constitutive MyD88-IRAK4 signaling for survival.